AI-designed 'universal vaccine' passes first human clinical trial, could prevent future pandemics
The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna. "They not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans. While traditional vaccines are reactive, a new AI-designed vaccine aims to protect against future coronavirus threats. (iStock)The universal-vaccine researchers said that a larger trial involving "a wider and more diverse population" is needed.
- ▪The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna.
- ▪"They not only protect against many variants simultaneously, but potentially against related viruses that haven’t yet emerged and spilt over to humans.
- ▪While traditional vaccines are reactive, a new AI-designed vaccine aims to protect against future coronavirus threats. (iStock)The universal-vaccine researchers said that a larger trial involving "a wider and more diverse population" is nee
Fox News — Latest files mainly under news. We currently carry 3,390 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Fox News |
| Canonical URL | https://www.foxnews.com/health/ai-designed-universal-vaccine-passes-first-human-clinical-trial-could-prevent-future-pandemics |
| Publication time | Sat, 13 Jun 2026 16:59:04 -0400 |
| Retrieval time | 2026-06-13T21:17:30.196Z |
| Last seen | 2026-06-13T21:17:30.196Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Jv4_abmEXqm1 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Coronavirus AI-designed 'universal vaccine' passes first human clinical trial, could prevent future pandemics Researchers say the vaccine protects against multiple Sarbeco coronaviruses simultaneously, including future variants By Teresa Mull Fox News Published June 13, 2026 4:59pm EDT Facebook Twitter Threads Flipboard Comments Print Email Add Fox News on Google close Video Cancer vaccine cuts melanoma risk nearly 50% in breakthrough study A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period. The personalized mRNA cancer therapy, combined with the cancer immunotherapy drug KEYTRUDA, is a collaboration between Merck and Moderna.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Fox News.
Discussion
0 commentsMore from Fox News
